Featured speakers

Meet some of our speakers here and learn more about their presentations at the 23rd Congress of EHA.
More information to follow on a weekly basis.

Dr Stefano Rivella

Sunday, June 17 - Plenary session II
Treating Thalassemia: Thinking “out of the box”

The presentation will focus on some of the discoveries that led to the present interpretation about the relationship about erythropoiesis and iron metabolism and how this is propelling drug discoveries in the field of anemia. It will also discuss unpublished data about potential novel mechanisms and treatments for beta-thalassemia.

Dr Gert Ossenkoppele

Saturday, June 16 - EHA-KSH Joint Symposium
AML

Visit my talk:
"Exciting new developments in the treatment of unfit patients with AML will be discussed".
"New hope for unfit AML patients".

Dr JH Lee

Saturday, June 16 - EHA-KSH Joint Symposium
AML

Optimal selection of chemotherapy regimens for induction treatment in acute myeloid leukemia will be discussed by Professor JH Lee.

Dr Hans-Reimer Rodewald

Friday, June 15 - EHA-JSH Joint Symposium
Hematopoiesis

“The Rodewald laboratory has developed new, non-invasive genetic fate mapping and barcoding experiments to unravel fundamental properties of the hematopoietic system, including output quantification from HSC in vivo (Busch et al. Nature 2015), identification of the yolk sac progenitors giving rise to tissue-resident macrophages (Gomez Perdiguero, Klapproth et al. Nature 2015), and determination of developmental fates realized by hematopoietic stem cells in vivo (Pei, Feyerabend et al. Nature 2017). The laboratory has discovered a key role for cell competition as a tumor suppressor mechanism preventing T cell acute lymphoblastic leukemia in the thymus (Martins et al. Nature 2014).“

Dr Koji Eto

Friday, June 15 - EHA-JSH Joint Symposium
Hematopoiesis

Professor Koji Eto will discuss on "revealing how a previously unknown physical stimulation regulates platelet shedding from human iPS cell-derived megakaryocytes, leading to the successful generation of over 100B (10e11) platelets ex vivo.''

Dr Tsvee Lapidot

Sunday, June 17 - Plenary Session 2
Healthy and malignant hematopoiesis in the bone marrow: Active cells in a dynamic environment

In this talk metabolic regulation of normal and leukemic stem cells in the bone marrow will be discussed.
In particular the roles of reactive oxygen species (ROS) and nitric oxide (NO) and their mode of action will be revealed.

Dr Charles Swanton

Saturday, June 16: EHA-ASH Joint Symposium
Cellular immunotherapy

Cancer genetic heterogeneity fuels natural selection and adaptation of tumours in the face of tumour microenvironmental change and cancer therapies. This talk will consider how tumours adapt under selection pressures and how the immune system constrains tumour growth. Novel therapeutic approaches targeting cancer evolution and leveraging the immune microenvironment will be discussed.

Dr Giampaolo Merlini

Sunday, June 17: Plenary Session 2
Amyloidosis: The rapidly changing face of diagnosis and therapy in AL amyloidosis

Formidable advances have been made during the last decade in deciphering the molecular mechanisms underlying AL amyloidosis and in the management of this complex and dreadful disease.
The combination of biomarkers and imaging united with increased awareness led to earlier diagnosis with a positive impact on patients’ outcome. Novel drugs are enriching the therapeutic landscape and immunotherapies aimed at accelerating the reabsorption of amyloid deposits are under development. The future lies in risk-adapted combination of anti-clone therapy and anti-amyloid treatments, holding promise of further improving the outlook in this now treatable disease.

Dr Markus Müschen

Saturday, June 16: Plenary Session 1
Autoimmunity checkpoints as therapeutic targets in B-cell malignancies

Unlike other types of cancer, B-cell malignancies are susceptible to negative selection and cell death induced by hyperactive signaling from an autoreactive B-cell receptor. While targeted therapy of cancer typically focuses on agents to suppress activity of oncogenes, Markus Müschen and colleagues introduce a new concept of targeted hyperactivation with the goal to trigger autoimmunity checkpoints and cell death in B-cell tumors.